Strategies to Treat Osteoporosis Following a Fragility Fracture

NACompletedINTERVENTIONAL
Enrollment

1,410

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2016

Conditions
OsteoporosisFractures
Interventions
BEHAVIORAL

Control group

Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered

BEHAVIORAL

Minimal Intervention

Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.

BEHAVIORAL

Intensive Intervention

"INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.~Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)"

Trial Locations (1)

J1H 5N4

Centre hospitalier universitaire de Sherbrooke, Sherbrooke

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Procter and Gamble

INDUSTRY

collaborator

Sanofi

INDUSTRY

collaborator

Novartis

INDUSTRY

collaborator

Amgen

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Servier

INDUSTRY

collaborator

Warner Chilcott

INDUSTRY

lead

Université de Sherbrooke

OTHER